

**Submission Data File**

<b>General Information</b>	
<b>Form Type*</b>	8-K
<b>Subject-Company File Number</b>	
<b>Subject-Company CIK</b>	
<b>Subject-Company Name</b>	
<b>Subject-Company IRS Number</b>	
Contact Name	Chris Pinilla
Contact Phone	212-596-7747
<b>Filer File Number</b>	
<b>Filer CIK*</b>	0001642375 <b>[Guardion Health Sciences, Inc.]</b> (Guardion Health Sciences, Inc.)
<b>Filer CCC*</b>	*****
Confirming Copy	No
Notify via Website only	No
Return Copy	No
<b>Group Name</b>	
<b>Items*</b>	8.01 Other Events
<b>SROS*</b>	NONE
<b>Depositor CIK</b>	
<b>Depositor 33 File Number</b>	
<b>Fiscal Year</b>	
<b>Item Submission Type</b>	
<b>Period*</b>	05-31-2018
<b>ABS Asset Class Type</b>	
<b>ABS Sub Asset Class Type</b>	
<b>Sponsor CIK</b>	
Emerging Growth Company	Yes
Elected not to use extended transition period	No
(End General Information)	

<b>Document Information</b>	
<b>File Count*</b>	1
<b>Document Name 1*</b>	tv495951_8k.htm
<b>Document Type 1*</b>	8-K
Document Description 1	8-K
(End Document Information)	

<b>Notifications</b>	
Notify via Website only	No
E-mail 1	chrispinilla@toppanlf.com
(End Notifications)	

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **May 31, 2018**

**GUARDION HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

0-55723  
(Commission  
File Number)

44-4428421  
(I.R.S. Employer  
Identification No.)

**15150 Avenue of Science, Suite 200  
San Diego, CA 92128**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(858) 605-9055**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On May 31, 2018, Guardion Health Sciences, Inc. (the “Company”) and certain warrant holders entered into agreements to extend the exercise period for warrants to purchase an aggregate of 372,848 shares of the Company’s common stock. Pursuant to the terms of a Note and Warrant Purchase Agreement entered into by the Company and the applicable warrant holders, such warrants were originally issued upon the conversion of certain promissory notes into common stock on May 1, 2015 and were originally scheduled to expire on May 1, 2018, but were previously extended to June 1, 2018 by agreement dated April 30, 2018. The warrants are now scheduled to expire on the earlier of (a) May 31, 2019 or (b) sixty (60) days following the date on which the common stock of the Company becomes listed or approved for listing on a national securities exchange. The exercise price of such warrants remains unchanged at \$1.00 per share, but cashless exercise provisions have been eliminated from such warrants.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GUARDION HEALTH SCIENCES, INC.**By: /s/ MICHAEL FAVISH

Name: Michael Favish

Title: Chief Executive Officer

Date: June 6, 2018